Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery

March 28, 2011 updated by: Abbott Nutrition
The primary objectives are to evaluate the effect of AN777 on muscle strength loss that occurs during bed rest, and to investigate whether AN777, in association with resistance training, will support muscle strength recovery following bed rest in healthy elderly subjects.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • University of Arkansas for Medical Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 79 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject (male or female) is > 60 to < 79 years of age.
  • Subject has Body Mass Index (BMI)> 20 < 35.
  • Subject is ambulatory with an SPPB score of > 9.
  • Subject agrees to comply with prescribed activity level.

Exclusion Criteria:

  • Subject has undergone major surgery, less than 4 weeks prior to enrollment in the study.
  • Subject has stated active malignant disease, except basal or squamous cell skin carcinoma or carcinoma in situ of the uterine cervix.
  • Subject has stated history of diabetes or fasting glucose value > 126 mg/dL.
  • Subject has stated presence of partial or full artificial limb.
  • Subject has stated kidney disease or serum creatinine > 1.4 mg/dL.
  • Subject has evidence of cardiovascular disease assessed during resting or exercise EKG.
  • Subject has untreated hypothyroidism with TSH levels greater than 5.5 microUnits/ml.
  • Subject has serum glutamate pyruvate transaminase (SGPT) levels greater than two times upper limit of laboratory-designated normal value.
  • Subject has a history of allergy to any of the ingredients in the study products.
  • Subject has an obstruction of the gastrointestinal tract precluding ingestion of the study product, inflammatory bowel disease, short bowel syndrome or other major gastrointestinal disease such as gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis.
  • Subject has stated uncontrolled severe diarrhea, nausea or vomiting.

Subject is actively pursuing weight loss.

  • Subject is currently taking medications/dietary supplements/substances that could modulate metabolism or weight in the opinion of the principal investigator or physician, e.g. progestational agents, steroids, growth hormone, dronabinol, marijuana, beta-hydroxyl-beta-methylbutyrate (HMB), free amino acid supplements, dietary supplements to aid weight loss. Exceptions for multi-vitamin/mineral supplement, inhaled steroids for asthma, topical or optical steroids and short-term use (less than two weeks) of Dexamethasone.
  • Subject cannot refrain from smoking/discontinue the use of nicotine or tobacco.
  • Subject has a stated history of Deep Vein Thrombosis (DVT) or a known hypercoaguable condition.
  • Subject cannot discontinue current anticoagulant therapy.
  • Subject has refractory anemia with hemoglobin value < 11.5 g/dL.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AN777
Powder twice a day
Powder twice a day
Placebo Comparator: Placebo powder
Powder twice a day
Powder twice a day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Lower extremity muscle strength changes after 10 days of bed rest, followed by changes after an 8-week recovery period.
Time Frame: 10 weeks
10 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Lower extremity lean body mass
Time Frame: 10 weeks
10 weeks
Muscle functionality
Time Frame: 10 weeks
10 weeks
Total lean mass
Time Frame: 10 weeks
10 weeks
physical activity levels
Time Frame: 10 weeks
10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Suzette Pereira, PhD, Abbott Nutrition

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2009

Primary Completion (Actual)

February 1, 2011

Study Completion (Actual)

March 1, 2011

Study Registration Dates

First Submitted

July 23, 2009

First Submitted That Met QC Criteria

July 23, 2009

First Posted (Estimate)

July 24, 2009

Study Record Updates

Last Update Posted (Estimate)

March 29, 2011

Last Update Submitted That Met QC Criteria

March 28, 2011

Last Verified

March 1, 2011

More Information

Terms related to this study

Other Study ID Numbers

  • BK37

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aged

Clinical Trials on Experimental Nutritional Powder Formula

Subscribe